A European randomised multicentre study of interferon alpha-2b versus no treatment after intensive therapy and Autologous hematopoeitic Stem Cell Transplantation (ASCT) for relapsing lymphoma patients

Start Date01 Jan 1999

Sponsor / Collaborator

Schering-Plough Ltd.

ISRCTN75847548 / CompletedPhase 3

Phase III study evaluating the efficacy of Drogenil in pancreatic carcinoma

Start Date01 Jan 1995

Sponsor / Collaborator

Schering-Plough Ltd.

ISRCTN92984394 / CompletedNot Applicable

A pilot study to assess flutamide monotherapy compared With maximal androgen blockade in metastatic prostate cancer

Start Date01 Jan 1994

Sponsor / Collaborator

Schering-Plough Ltd.

100 Clinical Results associated with Schering-Plough Ltd.

0 Patents (Medical) associated with Schering-Plough Ltd.

Literatures (Medical) associated with Schering-Plough Ltd.

01 Jun 2011·Rhinology journalQ1 · MEDICINE

Estimating the effect of nasal steroid treatment on repeat polypectomies: survival time analysis using the General Practice Research Database

Q1 · MEDICINE

Article

Author: Punekar, Y S ; Saleh, H A ; Ahmad, A

BACKGROUND: Intranasal steroids are effective in preventing or delaying recurrence of nasal polyps. However, their effectiveness in delaying a need for repeat polypectomy in clinical practice is unknown. OBJECTIVES: To compare time to a repeat polypectomy between post-polypectomy intranasal steroid users and non-users. METHODOLOGY/PRINCIPLE: Our cohort consisted of patients in GPRD who had undergone at least one nasal polypectomy procedure in or after the year 2000. These patients were followed for up to 4 years and the time to next polypectomy was estimated. Cox`s proportional hazards regression was used to estimate the effect of post polypectomy intranasal steroid treatment on time to the next polypectomy after controlling for other respiratory conditions and their treatment. RESULTS: The cohort consisted of 1,675 patients with a mean age of 59 years and 68% males. Of these, 576 patients were post-polypectomy steroid users and 1,099 patients were steroid non-users. The median time to repeat polypectomy was 812 days among the steroid users and 736 days among steroid non-users. Significantly less proportion of intranasal steroid users experienced a repeat polypectomy compared to steroid non-users. This difference was consistent among subgroups of females and concomitant rhinitis treatments users. Patients with post polypectomy intranasal steroid use showed lower risk for a repeat polypectomy compared to steroid non-users. Concomitant rhinitis medication users showed a higher risk whereas other confounders were not significant. CONCLUSIONS: Intranasal steroids were effective in delaying a repeat polypectomy. However, further research using a prospective design is necessary to quantify the benefit of ongoing steroid treatment.

01 Apr 2007·Current Medical Research and OpinionQ4 · MEDICINE

Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease

Q4 · MEDICINE

Article

Author: Chipperfield, R. ; Blagden, M. D.

OBJECTIVECombination of ezetimibe (EZE) with a statin represents an attractive strategy for cholesterol-lowering treatment, as it inhibits the two main sources of cholesterol: absorption from the intestine (inhibited by EZE) and endogenous biosynthesis (inhibited by statins).RESEARCH DESIGN AND METHODSThis multicentre, double-blind, placebo-controlled study randomised a total of 148 men and women with primary hypercholesterolaemia and coronary heart disease (CHD) to receive treatment for 6 weeks with either EZE 10 mg + atorvastatin 10 mg (EZE + ATV; n = 72) or placebo/atorvastatin 10 mg (ATV; n = 76). The primary efficacy variable was the mean percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to study endpoint.RESULTSAt 6 weeks, EZE + ATV provided a significantly greater adjusted mean change from baseline in LDL-C compared with ATV monotherapy (-50.5% vs. -36.5%; p < 0.0001), equating to an additional 14.1% reduction (95% CI -17.90, -10.19) in LDL-C. A significantly higher proportion of patients on EZE + ATV achieved the new Joint British Societies (JBS 2) recommended LDL-C goal of < 2 mmol/L (62% vs. 12% with ATV alone; p < 0.0001) and the JBS 2 minimum treatment standard of < 3 mmol/L (93% vs. 79% with ATV alone). Patients receiving EZE + ATV were 12 times more likely to reach LDL-C targets (odds ratio 12.1; 95% CI 5.8, 25.1; p < 0.0001) compared with patients receiving ATV monotherapy. Clinical chemistry profiles and the incidence of adverse events were similar in both groups.CONCLUSIONSAdding EZE to ATV monotherapy represents an attractive and well-tolerated treatment option to bring patients at high risk of CHD to the aggressive LDL-C goals recommended by recent treatment guidelines.

15 Dec 2006·American Journal of Health-System PharmacyQ4 · MEDICINE

Survey of pharmacist collaborative drug therapy management in hospitals

Q4 · MEDICINE

Article

Author: Lin, Shu-Wen ; Punekar, Yogesh ; Thomas, Joseph ; Bharmal, Murtuza

PURPOSEThe extent and scope of collaborative drug therapy management (CDTM) in U.S. hospitals and pharmacy directors' perceptions regarding CDTM were studied.METHODSA survey was developed after reviewing the literature on CDTM. The sample for the study was obtained from the 2001 American Hospital Association Guide. The mail survey was pretested in January 2002 with 30 hospital pharmacy directors in Illinois, Indiana, and Michigan. A national random sample of 1000 hospital pharmacy directors stratified by state were mailed surveys in March 2003. Two follow-up surveys were mailed at approximately four-week intervals.RESULTSResponses were received from 327 hospitals, a 32.7% response rate. A total of 158 respondents (49.7%) indicated that some pharmacists in their hospital were engaged in CDTM. Most hospitals with CDTM authorized pharmacists to adjust a drug's strength (86.7%), order laboratory or related tests (84.2%), and change a drug's frequency of administration (81.6%). The CDTM-related activities pharmacists performed varied with disease and treatment area. Payment or reimbursement for some CDTM was received by 12.7% of hospitals with CDTM. Respondents from hospitals with CDTM perceived significantly greater support for CDTM and greater strategic impact of CDTM than those from hospitals without CDTM. Respondents perceived positive support for CDTM but believed that CDTM had little or no financial impact on pharmacy departments.CONCLUSIONApproximately 50% of respondent hospitals had some pharmacists engaged in CDTM. Although CDTM was perceived as not having a positive financial impact on pharmacy departments, it was perceived as having a positive strategic impact by improving the views of upper administration regarding the value of pharmacists and facilitating implementation of other pharmacy services.

100 Deals associated with Schering-Plough Ltd.

100 Translational Medicine associated with Schering-Plough Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Peginterferon alfa-2b/Ribavirin(Merck & Co., Inc.) ( IFNAR x IMPDH x RNAP x RNGTT )	HIV Infections More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Schering-Plough Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 26 Nov 2024

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing